3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Keratosis, Actinic
6
Neoplasms
5
Melanoma
3
Warts
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Hyperthermia
2
Hematologic Neoplasms
2
Hemangioma
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Squamous Intraepithelial Lesions
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors Harboring NTRK Fusion
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Polycystic Ovary Syndrome
1
Pituitary Neoplasms
1
Pelvic Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Obesity
1
Nonmelanoma Skin Cancers
1
Mucositis
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Lymphoma, T-Cell
1
Lung Neoplasms
1
Interventions
Cisplatin
178
Paclitaxel
79
Radiotherapy
76
Carboplatin
70
Brachytherapy
69
pembrolizumab
63
Bevacizumab
40
Gemcitabine
28
Radiation
27
Topotecan
26
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
25
Nivolumab
22
Colposcopy
22
human papillomavirus vaccine, L1 type 16, 18
21
Magnetic Resonance Spectroscopy
21
Drug Therapy
20
atezolizumab
19
Platinum
19
Papillomavirus Vaccines
18
Radiotherapy, Intensity-Modulated
17
Docetaxel
17
Taxes
16
Cyclophosphamide
16
Biopsy
16
Early Intervention, Educational
15
1,2-diaminocyclohexaneplatinum II citrate
15
Methods
14
Blood Specimen Collection
14
fludarabine
13
Injections
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Uterine Cervical Neoplasms
×
Solutions
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled